Medicamen Biotech

522.75
+37.20
(7.66%)
ann
There are new updates from the company2 hours ago
Viewcross
right
Market Cap
664.66 Cr
EPS
7.50
PE Ratio
73.40
Dividend Yield
0.21 %
Industry
Healthcare
52 Week High
630.00
52 Week Low
375.05
PB Ratio
2.86
Debt to Equity
0.14
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Medicamen Biotech Signs CDMO Contract with European Company XGX PharmaToday
Medicamen Biotech has entered into a Contract Development and Manufacturing Organization (CDMO) agreement with XGX Pharma, a European pharmaceutical company. Under this contract, Medicamen will develop six products and manufacture them for XGX. The European company will hold the Marketing Authorization (MA) for these products.
positive
Medicamen Biotech Expands into Canadian and Australian Markets6 days ago
Medicamen Biotech has announced plans to expand its operations into Canada and Australia. This strategic move indicates the company's efforts to increase its global presence and potentially tap into new pharmaceutical markets.
positive
Medicamen Biotech Secures EU and USFDA Approvals for Manufacturing Plants6 days ago
Medicamen Biotech has successfully obtained approvals from both the European Union (EU) and the United States Food and Drug Administration (USFDA) for its manufacturing plants. This achievement signifies that the company's production facilities meet the stringent quality and safety standards required by these regulatory bodies, potentially opening up new markets and opportunities for the company's pharmaceutical products.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,765.90
#1 4,23,698.56
34.87
#1 49,887.20
12.06
#1 9,648
13.77
50.47
5,749.60
1,52,633.81
72.74
8,184.00
0.89
1,600
#1 64.53
46.20
1,498.90
1,21,053.40
23.51
26,520.70
14.17
4,155
47.38
45.27
3,243.50
1,09,774.78
58.33
10,785.70
11.59
1,656
13.54
55.87
2,418.35
99,775.93
48.93
10,615.60
19.57
1,942
-16.38
55.89
1,153.85
96,283.63
#1 17.86
28,905.40
12.36
5,578
1.69
45.11
2,093.35
95,570.00
31.98
20,141.50
#1 19.94
1,936
38.82
47.61
902.85
90,847.84
19.78
19,831.50
13.82
3,831
29.92
44.76
1,178.35
68,438.76
19.09
29,559.20
17.55
3,169
-10.04
52.27
30,109.95
63,981.54
47.09
6,097.20
10.80
1,201
16.01
44.78
Growth Rate
Revenue Growth
26.73 %
Net Income Growth
-35.37 %
Cash Flow Change
-7.15 %
ROE
-39.76 %
ROCE
-18.35 %
EBITDA Margin (Avg.)
-26.35 %

Quarterly Financial Results

Quarterly Financials
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
24
31
36
36
25
28
31
33
22
28
33
34
23
34
34
36
39
42
44
47
48
44
45
45
Expenses
20
26
30
30
21
24
25
28
17
22
26
26
18
27
28
30
32
35
39
42
42
40
39
38
EBITDA
4
5
6
6
4
4
6
5
5
6
7
7
5
7
6
7
7
7
5
6
6
4
6
7
Operating Profit %
18 %
16 %
16 %
15 %
13 %
15 %
18 %
16 %
20 %
22 %
19 %
19 %
22 %
17 %
17 %
17 %
17 %
17 %
11 %
11 %
12 %
8 %
12 %
15 %
Depreciation
1
1
1
1
1
1
1
1
0
1
1
2
2
2
2
2
2
2
2
2
2
2
3
2
Interest
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
2
1
1
1
Profit Before Tax
4
4
5
5
3
3
5
4
4
5
5
5
3
4
4
4
4
5
3
3
3
2
2
4
Tax
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
Net Profit
2
3
4
4
3
2
3
3
4
4
4
4
3
4
4
4
4
4
2
2
2
1
1
3
EPS in ₹
2.06
2.75
3.18
3.05
2.05
1.84
2.64
2.47
2.99
3.40
3.46
3.09
2.25
2.94
2.85
2.98
3.03
3.12
1.17
1.60
1.61
0.63
0.71
2.30

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
137
181
194
226
279
295
Fixed Assets
24
34
90
93
93
92
Current Assets
96
104
96
123
163
160
Capital Work in Progress
15
41
0
0
0
0
Investments
0
0
0
0
0
0
Other Assets
98
107
104
133
186
203
Total Liabilities
137
181
194
226
279
295
Current Liabilities
49
57
53
73
83
85
Non Current Liabilities
1
4
8
7
3
3
Total Equity
87
121
133
147
193
207
Reserve & Surplus
75
109
121
134
178
194
Share Capital
12
12
12
12
13
13

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
-14
-5
1
-0
17
-6
Investing Activities
-15
-37
-18
-9
-6
-6
Operating Activities
4
13
13
4
-6
-7
Financing Activities
-4
19
6
4
29
6

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
44.83 %
44.83 %
44.83 %
43.60 %
43.60 %
43.60 %
43.21 %
43.21 %
43.21 %
43.21 %
43.21 %
43.21 %
43.21 %
42.99 %
42.99 %
42.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.21 %
0.11 %
0.06 %
0.06 %
0.05 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.13 %
0.20 %
0.20 %
0.20 %
0.00 %
0.68 %
0.99 %
1.17 %
1.17 %
0.87 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.06 %
Public / Retail
33.04 %
32.97 %
33.17 %
34.23 %
34.30 %
35.02 %
30.94 %
31.35 %
31.49 %
31.43 %
31.80 %
31.90 %
31.95 %
31.57 %
32.43 %
32.96 %
Others
22.12 %
22.20 %
21.99 %
22.18 %
22.10 %
21.38 %
25.72 %
25.24 %
25.10 %
25.16 %
24.99 %
24.00 %
23.74 %
24.21 %
23.34 %
23.08 %
No of Share Holders
4,965
5,263
5,595
9,140
9,300
9,107
8,418
8,273
8,233
8,272
9,419
10,252
10,639
10,652
10,792
10,576

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 1 1 1 1 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.16 0.15 0.26 0.21 0.00

Corporate Action

Announcements

Announcment Under Regulation 30 (LODR)- Update2 hours ago
Closure of Trading Window3 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report5 days ago
Announcement Under Regulation 30 (LODR)- Expansion Into Regulated Markets And Long Term Vision6 days ago
Shareholder Meeting / Postal Ballot-Outcome of EGM7 days ago
Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations 2015Mar 22, 2025
Corrigendum-Notice Of The Extra Ordinary General Meeting Scheduled To Be Held On Wednesday March 26 2025 At 12:00 Noon Through Video Conferencing ("VC")/ Other Audio-Visuals Means ("OAVM")Mar 20, 2025
Announcement Under Regulation 30 (LODR) - UpdatesMar 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 04, 2025
Notice Of Extra Ordinary General Meeting - Wednesday March 26 2025Mar 03, 2025
Announcement Under Regulation 30 (LODR) - MBL Has Been Awarded By Honble Health Minister Of EthiopiaFeb 27, 2025
Announcement Under Regulation 30 (LODR) - MBL Has Been Awarded By Honble Health Minister Of EthiopiaFeb 27, 2025
Announcement under Regulation 30 (LODR)-Issue of SecuritiesFeb 26, 2025
Announcement under Regulation 30 (LODR)-Issue of SecuritiesFeb 26, 2025
Announcement Under Regulation 30 Of (LODR)- Clarification On Price MovementFeb 25, 2025
Announcement Under Regulation 30 Of (LODR)- Clarification On Price MovementFeb 25, 2025
Clarification sought from Medicamen Biotech LtdFeb 24, 2025
Board Meeting Intimation for Issunce Of One Or More Instruments Including Equity Shares/Convertible Securities Either By Way Of Preferential Issue/ Right Issue/QIP Or Any Other Mode.Feb 21, 2025
Announcement Under Regulation 30 (LODR)- Updates (Manufacturing And Supply Agreement)Feb 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 11, 2025
Financial Results For The Quarter Ended On 31.12.2024Feb 11, 2025
Integrated Filing (Financial)Feb 11, 2025
Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On December 31 2024Feb 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 22, 2025
Closure of Trading WindowDec 31, 2024
Clarification On Price MovementDec 06, 2024
Clarification sought from Medicamen Biotech LtdDec 06, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 06, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2024
Investor Presentation - Q2- 2024Nov 14, 2024
Outcome Of The Board Meeting Held On 14-11.2024Nov 14, 2024
Board Meeting Intimation for Considering Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On September 30,2024Nov 07, 2024
US FDA Approved The Sterile Injectable Oncology Formulation Facility At Haridwar And Establishment Inspection Report (EIR) ReleasedOct 25, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 09, 2024
Closure of Trading WindowOct 04, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 27, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 27, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2024
Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015Sep 18, 2024
EU GMP Certification Received For BHIWADI Formulation Facility Of Medicamen Biotech Limited.Sep 11, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2024
Corporate Action- Book Closure IntimationSep 02, 2024
Reg. 34 (1) Annual Report.Sep 02, 2024
31St Annual General MeetingSep 02, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2024
Business Responsibility and Sustainability Reporting (BRSR)Aug 13, 2024
Board Meeting Outcome for Outcome Of Board MeetingAug 13, 2024
Financial Results For The Quarter Ended On 30.06.2024Aug 13, 2024
Board Meeting Intimation for The Approval Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On June 30, 2024 And For Approval Of Draft Financial Results For The FY 2023-24Aug 07, 2024

Technical Indicators

RSI(14)
Neutral
53.51
ATR(14)
Less Volatile
31.48
STOCH(9,6)
Neutral
65.71
STOCH RSI(14)
Overbought
93.49
MACD(12,26)
Bullish
5.25
ADX(14)
Weak Trend
12.79
UO(9)
Bearish
46.30
ROC(12)
Uptrend And Accelerating
12.40
WillR(14)
Overbought
-16.14